Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

SK's $795M deal to usher Biohaven's epilepsy therapy towards FDA

26 August 2026 · By · Wire by Fusion42

Published

26 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at fiercebiotech.com →

◆ Verified

Fusion42 · 26 August 2026 · Fusion42 review

SK Biopharmaceuticals has acquired worldwide licensing rights to Biohaven's epilepsy therapy opakalim, paying $350 million upfront with potential total payments up to $795 million, aiming for a US launch by 2029. The deal accelerates Biohaven's treatment development while SK leverages its commercial experience to bring the therapy to market.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can expect tighter competition in epilepsy treatments as SK speeds Biohaven’s therapy to FDA submission, opening pathways for new players focused on US market launches. SK's move signals high value in epilepsy drug licences and faster commercial pathways for newcomers.

◆ Coverage

1 source · 26 Aug 2026

◆ Related on Wire

◆ Topics

Biotechepilepsydrug-licensingclinical-trialsbiohavensk-biopharma